The FDA has approved a companion diagnostic to determine if patients with HR-positive, HER2-ultralow metastatic breast cancer are eligible for T-DXd treatment.

The LNP-mRNA modality is a novel approach that uses lipid nanoparticles to deliver messenger RNA into cells. The mRNA acts as ...

I’ve started to notice that my pearly whites haven’t been looking so pearly lately. Which is why I jumped at the chance to ...